LRRK2 and Parkinson disease: Furthermore, these oral Pg-mediated harmful effects were accompanied by an increase in LRRK2935 expression, an indirect marker of LRRK2 kinase activity, which suggests the involvement of LRRK2 kinase in Pg-induced neuropathogenesis in LRRK2-associated PD.